DGIdb - CLOZAPINE Drug Record

CLOZAPINE chembl:CHEMBL42 Approved

Alternate Names:

CLOZAPINE RESOLUTION MIXTURE
HF-1854
CLOZARIL
FAZACLO
VERSACLOZ
ZAPONEX
CLOZAPINE
FAZACLO ODT
CLOZAPIN
CLOZAPINUM
CLORAZIL®
LEX123
CLOZAPINA
rxcui:2626
drugbank:00363
chembl:CHEMBL42
chemidplus:5786-21-0
pubchem.compound:2818

Drug Info:

FDA Approval	1989
Drug Class	small molecule
Drug Indications	Antipsychotic Agents
Drug Class	antipsychotic agents
Year of Approval	1989

(5 More Sources)

Publications:

Lipska et al., 2003, Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs., Eur. J. Neurosci.
Arranz MJ et al., 1998, Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response., Pharmacogenetics
Eum S et al., 2017, Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report., BMC Psychiatry
Sukasem C et al., 2016, Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders., J Clin Psychopharmacol
López-Rodríguez R et al., 2013, Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers., Pharmacogenomics
Roke Y et al., 2013, The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys., Pharmacogenet Genomics
Müller DJ et al., 2012, Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain., Pharmacogenomics J
Hong CJ et al., 2010, Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment., Pharmacogenet Genomics
Zhang JP et al., 2010, D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis., Am J Psychiatry
Yasui-Furukori N et al., 2008, Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients., Prog Neuropsychopharmacol Biol Psychiatry
Bakker PR et al., 2008, Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions., Mol Psychiatry
Alenius M et al., 2008, Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting., J Psychiatr Res
Zai CC et al., 2007, Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients., Mol Psychiatry
Suzuki A et al., 2001, The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients., Pharmacogenetics
Batra S, 1976, Unconjugated estradiol in the myometrium of pregnancy., Endocrinology
Ohara K et al., 1998, Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia., Psychiatry Res
Li T et al., 1998, Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia., Schizophr Res
Shen YC et al., 2009, Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients., J Psychiatr Res
Xing Q et al., 2007, The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients., Int J Neuropsychopharmacol
Lencz et al., 2006, DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients., Am J Psychiatry
Lerman C et al., 2006, Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials., Neuropsychopharmacology
Hwang R et al., 2005, Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations., Psychopharmacology (Berl)
Wu et al., 2005, Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients., Neurosci. Lett.
Yamanouchi Y et al., 2003, Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone., Pharmacogenomics J
Li T et al., 2002, Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABA(A)gamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects., Am J Med Genet
Young et al., 2004, Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele., Br J Psychiatry
Weizman et al., 2003, The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms., Eur. J. Pharmacol.
Green et al., 2002, Treatment of schizophrenia and comorbid substance use disorder., Curr Drug Targets CNS Neurol Disord
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Stonehouse et al., 2005, Bromocriptine and clozapine regulate dopamine 2 receptor gene expression in the mouse striatum., J. Mol. Neurosci.
Takano et al., 2006, Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations., Prog. Neuropsychopharmacol. Biol. Psychiatry
Tresadern G et al., 2011, Molecular properties affecting fast dissociation from the D2 receptor., Bioorg Med Chem
Schmitt et al., 2003, Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain., Neurosci. Lett.
Patel et al., 2003, Pharmacological and functional characterisation of dopamine D4 receptors in the rat retina., Neuropharmacology
Glatt et al., 2003, Schizophrenia is not associated with DRD4 48-base-pair-repeat length or individual alleles: results of a meta-analysis., Biol. Psychiatry
Zhao et al., 2005, Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine., Int. J. Neurosci.
Nakane et al., 2005, 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist., Neuropharmacology
Kuballa et al., Central effects of nafadotride, a dopamine D3 receptor antagonist, in rats. Comparison with haloperidol and clozapine., Pharmacol Rep
Hwang R et al., 2007, Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response., J Psychopharmacol
Tiwari AK et al., 2010, Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients., Prog Neuropsychopharmacol Biol Psychiatry
Piatkov I et al., 2017, CYP2C19*17 protects against metabolic complications of clozapine treatment., World J Biol Psychiatry
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Leysen et al., 1994, Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity., J Clin Psychiatry
Roegge et al., 2007, Histamine H1 receptor involvement in prepulse inhibition and memory function: relevance for the antipsychotic actions of clozapine., Pharmacol. Biochem. Behav.
Kontkanen et al., 2002, Chronic antipsychotic drug treatment induces long-lasting expression of fos and jun family genes and activator protein 1 complex in the rat prefrontal cortex., Neuropsychopharmacology
Navailles et al., 2006, Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo., Biol. Psychiatry
Sodhi et al., 2005, A rapid new assay to detect RNA editing reveals antipsychotic-induced changes in serotonin-2C transcripts., Mol. Pharmacol.
Ma X et al., 2014, HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis., Int J Psychiatry Clin Pract
Houston JP et al., 2012, Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia., J Clin Psychiatry
Sicard MN et al., 2010, Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis., Pharmacogenomics
Risselada AJ et al., 2012, Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study., Pharmacogenomics J
Opgen-Rhein C et al., 2010, Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample., Pharmacogenomics
Godlewska BR et al., 2009, Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene., Pharmacogenomics J
Mulder H et al., 2009, HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study., J Clin Psychopharmacol
Mulder H et al., 2007, The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia., J Clin Psychopharmacol
Mulder H et al., 2007, The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study., Pharmacogenomics J
Roth et al., 1994, Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors., J. Pharmacol. Exp. Ther.
Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry
Lacivita E et al., 2012, Investigations on the 1-(2-biphenyl)piperazine motif: identification of new potent and selective ligands for the serotonin(7) (5-HT(7)) receptor with agonist or antagonist action in vitro or ex vivo., J Med Chem
Goldstein, 1999, Quetiapine fumarate (Seroquel): a new atypical antipsychotic., Drugs Today
Reist et al., 2004, Inter-relationships of intermediate phenotypes for serotonin function, impulsivity, and a 5-HT2A candidate allele: His452Tyr., Mol. Psychiatry
McDonald et al., 2003, Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning., Psychopharmacology (Berl.)
Heiser et al., 2004, Effects of clozapine and its metabolites on the 5-HT2 receptor system in cortical and hippocampal cells in vitro., Prog. Neuropsychopharmacol. Biol. Psychiatry
Broderick et al., 2004, Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal., Prog. Neuropsychopharmacol. Biol. Psychiatry
Travis et al., 1998, 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150., Br J Psychiatry
Arranz et al., 1996, Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine., Neurosci. Lett.
Salloum NC et al., 2014, Towards the clinical implementation of pharmacogenetics in bipolar disorder., BMC Med
Shao et al., 2006, Antipsychotic drugs cause glial cell line-derived neurotrophic factor secretion from C6 glioma cells., J Psychiatry Neurosci
Dettling M et al., 2001, Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample., Arch Gen Psychiatry
Hwang R et al., 2011, Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response., Pharmacogenomics
Hwang R et al., 2010, Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant., Pharmacogenomics J
Smits et al., 2006, Characterization of the histamine H4 receptor binding site. Part 1. Synthesis and pharmacological evaluation of dibenzodiazepine derivatives., J. Med. Chem.
Sugata et al., 2007, Histamine H4 receptor agonists have more activities than H4 agonism in antigen-specific human T-cell responses., Immunology
Adachi et al., 2006, Suppression of ischemia/reperfusion liver injury by histamine H4 receptor stimulation in rats., Eur. J. Pharmacol.
Bosia M et al., 2015, COMT Val158Met and 5-HT1A-R -1019 C/G polymorphisms: effects on the negative symptom response to clozapine., Pharmacogenomics
Chou et al., 2003, Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study., Psychopharmacology (Berl.)
Newman-Tancredi et al., 2003, Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924., Naunyn Schmiedebergs Arch. Pharmacol.
Tomić et al., 2004, Pharmacological evaluation of selected arylpiperazines with atypical antipsychotic potential., Bioorg. Med. Chem. Lett.
Zahorodna et al., 2004, The influence of repeated administration of clozapine and haloperidol on the effects of the activation of 5-HT(1A), 5-HT(2) and 5-HT(4) receptors in rat frontal cortex., J. Physiol. Pharmacol.
Hagino et al., 2002, Effects of clozapine on the efflux of serotonin and dopamine in the rat brain: the role of 5-HT1A receptors., Can. J. Physiol. Pharmacol.
Valevski A et al., 1998, HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients., Eur J Immunogenet
Saito T et al., 2016, Pharmacogenomic Study of Clozapine-Induced Agranulocytosis/Granulocytopenia in a Japanese Population., Biol Psychiatry
Lieberman JA et al., 1990, HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia., Arch Gen Psychiatry
Wittmann et al., 2005, Clozapine potentiation of N-methyl-D-aspartate receptor currents in the nucleus accumbens: role of NR2B and protein kinase A/Src kinases., J. Pharmacol. Exp. Ther.
Mitjans M et al., 2015, Hypothalamic-pituitary-adrenal system, neurotrophic factors and clozapine response: association with FKBP5 and NTRK2 genes., Pharmacogenet Genomics
Dragovic S et al., 2013, Characterization of human cytochrome P450s involved in the bioactivation of clozapine., Drug Metab Dispos
Chetty et al., 2007, CYP-mediated clozapine interactions: how predictable are they?, Curr. Drug Metab.
Nurmi EL et al., 2013, Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies., Transl Psychiatry
Monteleone P et al., 2010, Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain., J Clin Psychopharmacol
Tiwari AK et al., 2010, A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia., Neuropsychopharmacology
Fernø et al., 2006, Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs., BMC Neurosci
Delacrétaz A et al., 2017, Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs., Gene
Brandl EJ et al., 2016, The role of the ITIH3 rs2535629 variant in antipsychotic response., Schizophr Res
Rajkumar AP et al., 2012, Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia., Psychopharmacology (Berl)
Souza RP et al., 2010, Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia., Pharmacogenet Genomics
Xu M et al., 2010, Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia., Prog Neuropsychopharmacol Biol Psychiatry
Kang et al., 2004, The effects of clozapine on the GSK-3-mediated signaling pathway., FEBS Lett.
Brandl EJ et al., 2014, Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain., Pharmacogenomics
Dettling M et al., 2001, Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry., Pharmacogenetics
Szuster-Ciesielska et al., Neuroleptics modulate cytokine and reactive oxygen species production in blood leukocytes of healthy volunteers., Arch. Immunol. Ther. Exp. (Warsz.)
Kobayashi et al., 2000, Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K(+) (GIRK) channels expressed in xenopus oocytes., Br. J. Pharmacol.
Kao AC et al., 2014, Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances., J Psychiatr Res
Atmaca et al., 2003, Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics., J Clin Psychiatry
Porcelli S et al., 2016, PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study., Neuropsychobiology
Zhang JP et al., 2016, Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis., Schizophr Bull
Czerwensky F et al., 2013, MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?, Int J Neuropsychopharmacol
Malhotra AK et al., 2012, Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain., Arch Gen Psychiatry
Chowdhury NI et al., 2013, Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene., Pharmacogenomics J
van der Weide K et al., 2017, Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population., Pharmacogenomics J
Kohlrausch FB et al., 2010, Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics., J Psychiatr Res
Lara et al., 2001, Chronic treatment with clozapine, but not haloperidol, increases striatal ecto-5'-nucleotidase activity in rats., Neuropsychobiology
Taylor DL et al., 2016, Genetic association analysis of N-methyl-D-aspartate receptor subunit gene GRIN2B and clinical response to clozapine., Hum Psychopharmacol
Lieberman et al., 1994, Predictors of response to clozapine., J Clin Psychiatry
Brandl EJ et al., 2013, Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain., Hum Psychopharmacol
Jaquenoud Sirot E et al., 2009, ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine., J Clin Psychopharmacol
Palma BB et al., 2010, Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression., Pharmacogenomics J
Bolla E et al., 2011, Are CYP1A21F and 1C associated with clozapine tolerability?: a preliminary investigation., Psychiatry Res
Kohlrausch FB et al., 2013, The CYP1A2 -163C>A polymorphism is associated with clozapine-induced generalized tonic-clonic seizures in Brazilian schizophrenia patients., Psychiatry Res
Lee ST et al., 2012, Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response., J Clin Psychopharmacol
Erickson-Ridout KK et al., 2012, Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms., Pharmacogenet Genomics
Zhang C et al., 2017, Complement 3 and metabolic syndrome induced by clozapine: a cross-sectional study and retrospective cohort analysis., Pharmacogenomics J

CLOZAPINE ITIH3

Interaction Score: 2.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27396837

Sources:
PharmGKB
CLOZAPINE JUND

Interaction Score: 2.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12093589

Sources:
NCI
CLOZAPINE TBC1D1

Interaction Score: 1.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23364847

Sources:
PharmGKB
CLOZAPINE HLA-DPB1

Interaction Score: 1.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11266078

Sources:
PharmGKB
CLOZAPINE ANKK1

Interaction Score: 0.79

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26872113 23859574 23851570 20714340 18579277 18180754 18086475 17767146

Sources:
PharmGKB
CLOZAPINE C3

Interaction Score: 0.7

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26503818

Sources:
PharmGKB
CLOZAPINE HLA-DRB3

Interaction Score: 0.7

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11266078

Sources:
PharmGKB
CLOZAPINE KCNJ3

Interaction Score: 0.7

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10780978

Sources:
NCI
CLOZAPINE HRH4

Interaction Score: 0.63

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
16854056 17346280 11752352 16860312

Sources:
TdgClinicalTrial TEND
CLOZAPINE HLA-DRB5

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11146763

Sources:
PharmGKB
CLOZAPINE MC4R

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27217270 23920449 23799528 22566560 22310352

Sources:
PharmGKB
CLOZAPINE GDNF

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16496033

Sources:
NCI
CLOZAPINE SLC1A1

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12873733

Sources:
NCI
CLOZAPINE EPM2A

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27092952

Sources:
PharmGKB
CLOZAPINE HTR2C

Interaction Score: 0.29

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
16182256 15917433 25152019 22967772 21121776 20680028 20504252 19434072 19142101 17632216 17016522

Sources:
TdgClinicalTrial TEND PharmGKB
CLOZAPINE DTNBP1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CLOZAPINE DRD2

Interaction Score: 0.24

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

Mechanism of Interaction Dopamine D2 receptor antagonist

PMIDs:
12887421 9918131 28673279 26872113 23859574 23851570 20714340 20375926 20194480 18579277 18180754 18086475 17767146 11505224 991813 9858029 9713903 18926547 17105675 16513877 16123753 15830237 15694263 14610521 11920858 15286066 14575800 12769622 11752352 15781964 16040180 21421319

Sources:
DTC TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB
CLOZAPINE RABEP1

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28694205

Sources:
PharmGKB
CLOZAPINE SH2B1

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28694205

Sources:
PharmGKB
CLOZAPINE HTR7

Interaction Score: 0.23

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
7908055 17848919 22738316

Sources:
DTC NCI
CLOZAPINE DRD4

Interaction Score: 0.22

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
12763097 13129658 16223700 15992586 11752352 15886414

Sources:
TdgClinicalTrial TEND TTD
CLOZAPINE GSTT1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27168101

Sources:
PharmGKB
CLOZAPINE HLA-C

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11266078

Sources:
PharmGKB
CLOZAPINE FKBP5

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25751398

Sources:
PharmGKB
CLOZAPINE HTR1A

Interaction Score: 0.17

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
25560469 12589516 12923612 15261283 15213359 12564641

Sources:
TdgClinicalTrial TEND PharmGKB
CLOZAPINE HLA-B

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9587740 26876947 2222133

Sources:
PharmGKB
CLOZAPINE NT5E

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11490180

Sources:
NCI
CLOZAPINE HTR2A

Interaction Score: 0.15

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Serotonin 2a (5-HT2a) receptor antagonist

PMIDs:
7520908 12973385 15037867 14530903 14751426 14687870 9926100 8916101 24885933

Sources:
TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB
CLOZAPINE LEP

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12755665

Sources:
NCI
CLOZAPINE CCKBR

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20732371

Sources:
PharmGKB
CLOZAPINE GCG

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24624910

Sources:
PharmGKB
CLOZAPINE CNR1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23799528 20631561 20107430

Sources:
PharmGKB
CLOZAPINE GSTM1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27168101

Sources:
PharmGKB
CLOZAPINE FAAH

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20631561

Sources:
PharmGKB
CLOZAPINE FASN

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17052361

Sources:
NCI
CLOZAPINE HTR3A

Interaction Score: 0.1

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
22700043 20168265 17848919

Sources:
PharmGKB
CLOZAPINE MTHFR

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24725652

Sources:
PharmGKB
CLOZAPINE IL2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15053234

Sources:
NCI
CLOZAPINE COMT

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25560469

Sources:
PharmGKB
CLOZAPINE DRD3

Interaction Score: 0.06

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
21332319 20029384 17848919

Sources:
PharmGKB
CLOZAPINE PRL

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7961556

Sources:
NCI
CLOZAPINE UGT1A1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22565219

Sources:
PharmGKB
CLOZAPINE GRIN2B

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26876050

Sources:
PharmGKB
CLOZAPINE NTRK2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25751398

Sources:
PharmGKB
CLOZAPINE HRH1

Interaction Score: 0.04

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
7520908 17382376 11752352

Sources:
TdgClinicalTrial TEND
CLOZAPINE SLC6A3

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20580759

Sources:
PharmGKB
CLOZAPINE SLC6A4

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20452607

Sources:
PharmGKB
CLOZAPINE DRD1

Interaction Score: 0.04

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
17092969 11752352

Sources:
DTC TdgClinicalTrial TEND PharmGKB
CLOZAPINE SRC

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15659539

Sources:
NCI
CLOZAPINE PIK3CG

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14988008

Sources:
NCI
CLOZAPINE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27168101 22722500 19593168

Sources:
PharmGKB
CLOZAPINE GLP1R

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24624910

Sources:
PharmGKB
CLOZAPINE CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300 19593168 20125119 21481946 23601795

Sources:
DTC PharmGKB
CLOZAPINE CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28664816 22931300

Sources:
DTC PharmGKB
CLOZAPINE CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23297297 22931300 17504220

Sources:
DTC NCI PharmGKB
CLOZAPINE CBX1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CLOZAPINE CYP2C9

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CLOZAPINE POLI

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CLOZAPINE CYP2D6

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
FDA

TEND: CLOZAPINE
- Version: 01-August-2011
Alternate Names:

CLOZAPINE Primary Drug Name

Drug Info:

Year of Approval 1989

Drug Class antipsychotic agents

Publications:
TdgClinicalTrial: CLOZAPINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antipsychotic Agents

Drug Class small molecule

FDA Approval 1989

Publications:

NCI: CLOZAPINE

Version: 14-September-2017

Alternate Names:

C28936 NCI drug code

Drug Info:

Publications:

Lipska et al., 2003, Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs., Eur. J. Neurosci.

Schmitt et al., 2003, Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain., Neurosci. Lett.

Chetty et al., 2007, CYP-mediated clozapine interactions: how predictable are they?, Curr. Drug Metab.

DTC: CLOZAPINE

Version: 02-September-2020

Alternate Names:

CHEMBL42 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Lacivita E et al., 2012, Investigations on the 1-(2-biphenyl)piperazine motif: identification of new potent and selective ligands for the serotonin(7) (5-HT(7)) receptor with agonist or antagonist action in vitro or ex vivo., J Med Chem

Tresadern G et al., 2011, Molecular properties affecting fast dissociation from the D2 receptor., Bioorg Med Chem

PharmGKB: clozapine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Tiwari AK et al., 2010, Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients., Prog Neuropsychopharmacol Biol Psychiatry

Li T et al., 1998, Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia., Schizophr Res

Müller DJ et al., 2012, Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain., Pharmacogenomics J

TTD: Clozapine
- Version: 2020.06.01
Alternate Names:

D0Z1RV TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL42
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL42
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
FDA: Clozapine
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Novel drug target	Established target
Trial Name	-
Mechanism of Interaction	Dopamine D2 receptor antagonist

CLOZAPINE Drug Record

CLOZAPINE chembl:CHEMBL42 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27396837

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12093589

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23364847

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11266078

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26872113 23859574 23851570 20714340 18579277 18180754 18086475 17767146

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26503818

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11266078

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10780978

Sources: NCI

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 16854056 17346280 11752352 16860312

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11146763

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27217270 23920449 23799528 22566560 22310352

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16496033

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12873733

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27092952

Sources: PharmGKB

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 16182256 15917433 25152019 22967772 21121776 20680028 20504252 19434072 19142101 17632216 17016522

Sources: TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Novel drug target Established target Trial Name - Mechanism of Interaction Dopamine D2 receptor antagonist

PMIDs: 12887421 9918131 28673279 26872113 23859574 23851570 20714340 20375926 20194480 18579277 18180754 18086475 17767146 11505224 991813 9858029 9713903 18926547 17105675 16513877 16123753 15830237 15694263 14610521 11920858 15286066 14575800 12769622 11752352 15781964 16040180 21421319

Sources: DTC TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28694205

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28694205

Interaction Types & Directionality:

n/a

PMIDs:
27396837

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12093589

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
23364847

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11266078

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26872113 23859574 23851570 20714340 18579277 18180754 18086475 17767146

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26503818

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11266078

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
10780978

Sources:
NCI

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
16854056 17346280 11752352 16860312

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
11146763

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27217270 23920449 23799528 22566560 22310352

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16496033

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12873733

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
27092952

Sources:
PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
16182256 15917433 25152019 22967772 21121776 20680028 20504252 19434072 19142101 17632216 17016522

Sources:
TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

Mechanism of Interaction Dopamine D2 receptor antagonist

PMIDs:
12887421 9918131 28673279 26872113 23859574 23851570 20714340 20375926 20194480 18579277 18180754 18086475 17767146 11505224 991813 9858029 9713903 18926547 17105675 16513877 16123753 15830237 15694263 14610521 11920858 15286066 14575800 12769622 11752352 15781964 16040180 21421319

Sources:
DTC TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28694205

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28694205

Sources:
PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

PMIDs:
7908055 17848919 22738316

Sources:
DTC NCI

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
12763097 13129658 16223700 15992586 11752352 15886414

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
27168101

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11266078

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25751398

Sources:
PharmGKB

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
25560469 12589516 12923612 15261283 15213359 12564641

Sources:
TdgClinicalTrial TEND PharmGKB